Primitive neuroectodermal tumors (PNET) are highly malignant group of neoplasm of soft tissue that affects both children and adults. These malignant tumors are small round cells with neuroectodermal origin affecting soft tissues and bones rapidly. PNET was first described by Stout in 1918 and were thought to rise from the nerves. Peripheral primitive neuroectodermal tumors (pPNETs) are classified in the Ewing family of tumors (EFTs). Both these tumors have similar genetic alterations with different manifestations, and so are indistinguishably referred in the medical literature. Soft tissue tumors are associated prominently with peripheral primitive neuroectodermal tumors, while Ewing sarcoma is associated with bone tumor. These primitive neuroectodermal tumors have various clinical and pathological characteristics similar to many other types of small and round tumors. Hence, Batsakis et al in 1996 classified PNET family into three types based on the origin of tumor. The three types of PNET are CNS primitive neuroectodermal tumors (derived from the central nervous system), neuroblastoma (derived from autonomic nervous system), and peripheral primitive neuroectodermal tumors (originate from tissues other than autonomic or central nervous system).
Multidisciplinary therapeutic options are utilized for the treatment of PNET including surgery, chemotherapy, radiation therapy, and ventriculoperitoneal shunt. Surgery is carried out primarily for diagnosis and then for tumor removal. Removal of tumor is usually possible if it is supratentorial, and is less frequent in case of spine or pineal region. Radiation therapy is recommended if the tumor is not completely eradicated or if it reappears. Radiation therapy is followed by chemotherapy in order to interfere with growth or reproduction of the cancer. Ventriculoperitoneal shunt is a bypass, wherein a tubing is placed in the brain area in order to drain excess cerebrospinal fluid to space into the abdomen. Endoscopic third ventriculostomy is necessary in case of hydrocephalus (swelling of the brain).
The malignant nature of tumor is a major driver of the primitive neuroectodermal tumors treatment market owing to the recommended use of combination of therapies to combat aggressive nature of tumor. Recent advances in molecular diagnosis and cancer therapeutic combination treatments is expected to boost the growth of the primitive neuroectodermal tumors treatment market during the forecast period. Threat of drug failure, severe side effects of therapeutics, and high cost of research & development of better therapeutic options are expected to restrain the global primitive neuroectodermal tumors treatment market during the forecast period. However, rise in government funds and increase in awareness among the population about fatal diseases in emerging nations are expected to support the growth of the global primitive neuroectodermal tumors treatment market.
The global primitive neuroectodermal tumors treatment market can be segmented based on tumor type, treatment type, distribution channel, and region. In terms of tumor type, the market can be categorized into CNS primitive neuroectodermal tumors, neuroblastoma, and peripheral primitive neuroectodermal tumors. Based on treatment type, the global primitive neuroectodermal tumors treatment market can be classified into surgery, chemotherapy, radiation therapy, ventriculoperitoneal shunt, and others. In terms of distribution channel, the market can be divided into hospital pharmacies, drug stores, online pharmacies, and others. Based on region, the global primitive neuroectodermal tumors treatment market can be categorized into North America, Latin America, Asia Pacific, Europe, and Middle East & Africa.
Major players dominating the global primitive neuroectodermal tumors treatment market include Eli Lilly and Company, Novartis AG, Pfizer, Sanofi, GlaxoSmithKline plc, and Merck & Company.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.